“Life! Life! Do you hear me?! Give my creation LIIIIIIFE!” So shrieked the mad scientist Dr. Frankenstein, pronounced FRONK-en-steen and played by the illustrious Gene Wilder, in the scene where the late Peter Boyle comes to life as the most recent rendition of the Frankenstein monster.
I imagine that in similar fashion pharmaceutical company GlaxoSmithKline is now appealing to the FDA to give life to its most recent creation. Dubbed the “Son of Advair”, this once-daily combo drug called Breo in the U.S., is slated to replace its twice-daily predecessor Advair. Showing some promise in clinical trials and slated in the U.S. for COPD patients only. As a once-daily LAMA/LABA combination, Breo could significantly improve patient compliance with their medication reducing symptoms associated with COPD.
This means better self management of their own disease state, potential improvements in quality of life and perhaps decreased ER visits and hospital admissions for these patients. Giving life to the “Son of Advair” could translate into real cost savings and better life for COPD patients. Not bad for a few mad scientists!